Malaria remains one of the most widespread infectious diseases of the world. More than 85 per cent of malaria cases and 90 per cent of malaria deaths occur in Sub-Saharan Africa, mainly in young children below five years of age[@ref1]. Incidences of chloroquine (CQ) resistance were first reported in the late 1950s from South-East Asia and South America[@ref2]. In India, the first CQ-resistant *Plasmodium falciparum* case was documented in 1973 from the North-East Karbi - Anglong district of Assam[@ref3]. In 1982, the National Antimalarial Drug Policy was introduced to improve malaria case management and sulphadoxine-pyrimethamine (SP) combination was recommended as the treatment for CQ-resistant malaria[@ref4]. In November 1984, mefloquine (MQ) was introduced as the first-line treatment for uncomplicated falciparum malaria in Thailand, but despite careful regulation of its use, substantial resistance was developed within five years and emerged in adjacent countries, such as Burma and Cambodia[@ref5]. Western Cambodia and Thailand-Myanmar border were the regions of greatest concern because resistance to both MQ and SP emerged in this area[@ref6]. To overcome the problem associated with resistant falciparum malaria, artemisinin-based combination therapy (ACT), which included artesunate+MQ, artemether (ARTM)+lumefantrine (LUME) and artesunate+amodiaquine, was recommended as a first-line antimalarial treatment[@ref7][@ref8][@ref9][@ref10]. However, the artemisinin class of drugs have also shown signs of reduced efficacy[@ref11][@ref12][@ref13][@ref14] providing a potential threat to ACT. In 1994, two randomized trials were carried out in Western Cambodia (Pailin) and North-western Thailand (Wang Pha) by Dondorp *et al*[@ref11], who gave two regimens of artesunate treatment *i.e*. 2 mg/kg/day for seven days and 4 mg/kg/day for three days, followed by 25 mg/kg of MQ given in two doses. The results revealed that median parasite clearance times were 84 and 48 h in Pailin and Wang Pha, respectively, and recrudescence occurred in 30 per cent patients receiving artesunate monotherapy and in five per cent patients receiving artesunate-MQ combination therapy in Pailin, as compared with 10 and 5 per cent, respectively in Wang Pha. However, no reduction in *in vitro* susceptibility was observed by Dondorp *et al*[@ref11]. Another long-term study[@ref13] was carried out on 3202 patients in north-western border of Thailand. During this study, the patients received various artesunate-containing therapies between 2001 and 2010. The findings revealed that 'genetically determined artemisinin resistance in *P. falciparum* emerged along the Thailand-Myanmar border at least eight years ago and has increased substantially and may reach in Western Cambodia in 2-6 yr[@ref13]. In 2012, Amaratunga *et al*[@ref14] explored the involvement of malaria parasite genetics and host factors towards the development of artemisinin resistance in six districts of Pursat, Western Cambodia. They gave participants 4 mg/kg artesunate at 0, 24 and 48 h, 15 mg/kg mefloquine at 72 h and 10 mg/kg mefloquine at 96 h and assessed parasite density on thick blood films every six hours until undetectable. The parasite clearance half-life was calculated. The findings revealed artemisinin resistance in Pursat. Thus, the area in Western Cambodia, especially along the border with Thailand, is considered the world\'s hot spot for *P. falciparum* multidrug resistance[@ref15][@ref16][@ref17][@ref18]. A molecular marker (K13-propeller) has been developed as a tool to monitor the spread of artemisinin-resistant mutations[@ref19][@ref20]. Tun *et al*[@ref20] observed that in Homalin, Sagaing Region in Myanmar, 25 km from the Indian border, 21 (47%) of 45 parasite samples exhibited K13-propeller mutations. The present study was undertaken to explore *in vitro* chemosensitivity of four Indian field isolates of *P. falciparum* collected from Mizoram, a north-eastern State of India, against standard antimalarial drugs and antibiotics.

Material & Methods {#sec1-2}
==================

This study was conducted in the division of Parasitology, CSIR-Central Drug Research Institute (CDRI), Lucknow, India.

 {#sec2-1}

### Parasites {#sec3-1}

[Field isolates:]{.ul} Cryopreserved vials of four field isolates (MZR-I, MZR-II, MZR-III and MZR-IV) of *P. falciparum*, obtained from Mizoram in 2008, were procured from ICMR-National Institute of Malaria Research (NIMR), New Delhi. The four isolates were collected from four patients who exhibited dihydro-artemisinin (DHA)-piperaquine (PPQ) combination treatment failure.

[Reference strains:]{.ul} (*i*) 3D7 chloroquine (CQ) sensitive strain - This parasite strain is maintained in CSIR-CDRI. It is a clone derived from NF54 strain; the original isolate was obtained from a patient living near Schiphol Airport, Amsterdam[@ref21]; (*ii*) K1 strain (MRA159) CQ-resistant strain - This strain was obtained from MR4, American Type Cell Culture (ATCC), Manassas, Virginia, USA.

*In vitro cultivation of parasite*: Four field isolates (erythrocytic stages) were revived and maintained in 5 ml culture medium (RPMI-1640; Sigma, USA, R4130-1L) at 3 per cent haematocrit suspension \[human red blood cells (RBCs)\]. The culture medium was prepared as described elsewhere[@ref22]. AlbuMAX-II (GIBCO, New Zealand; 11021/045) 0.5 and 10 per cent foetal bovine serum (FBS, Sigma, F2442/HYCLONE, SH30396.03HI) were used as serum supplements. The cultures were maintained stationary at 37°C in a CO~2~ incubator (Thermo Electron Corporation, USA; water jacketed, model no. 3131) in the atmosphere of five per cent CO~2~ and air mixture. The per cent parasitaemia (%P) was monitored daily. The *in vitro* culture of both reference strains was also maintained in the laboratory.

*Assessment of per cent parasitaemia (%P)*: The Giemsa-stained blood smears were examined under the light microscope (100×, oil immersion, Nikon, Japan). Approximately 10,000 RBCs per smear were scanned and %P was calculated as number of parasitized RBCs (PRBCs)/total number of RBCs × 100.

Assessment of growth profile of field isolates:%P of all the parasites was monitored daily to determine the comparative growth profile of field isolates (MZR-I, MZR-II, MZR-III and MZR-IV) and reference parasite strains (3D7 and K1). Three replicates were carried out for each parasite isolate.

*Assessment of chemosensitivity of field isolates*: Fifty and 90 per cent inhibitory concentration (IC~50~ and IC~90~) values of standard antimalarials and antibiotics were determined using malaria SYBR Green I fluorescence assay[@ref23] and compared with those obtained against 3D7 and K1 parasites.

*Drugs used*: Chloroquine diphosphate (CQ), quinine hydrochloride dihydrate (QUIN), mefloquine hydrochloride (MQ), PPQ, ARTM, arteether (ARTE), DHA, LUME and atovaquone (ATQ) and antibiotics, azithromycin (AZI) and doxycycline (DOXY) were used for the assessment of chemosensitivity. CQ (C6628), QUIN (Q1125), MQ (M2319) and ATQ (A7986) were purchased from Sigma while PPQ, ARTM, ARTE, DHA and LUME were obtained (as gift) from IPCA Laboratories Ltd., Mumbai. The antibiotics were purchased from Biogene, USA.

*Preparation of drugs*: Stock solutions (10 mM) of all the drugs was prepared in dimethyl sulphoxide (DMSO) except CQ and PPQ which were prepared in sterile water. The subsequent dilutions were prepared in CRPMI (RPMI-1640 with 10% FBS and 9.2 μM hypoxanthine).

*Evaluation of IC~50~ and IC~90~ values*: CRPMI (50 μl) was dispensed in each well of 96-well flat bottom plate, followed by the addition of 50 μl test sample constituting 4× highest concentration in duplicate wells in row 'B' and 2-fold serial dilutions were made up to row 'H\'. To obtain best-fit curve, highest concentrations of the same drug varied amongst parasite strains as depicted in ([Table I](#T1){ref-type="table"}). The 50 μl volume from wells of row H was discarded. Subsequently, 50 μl of 2.0 per cent PRBCs suspension containing 1.0 per cent parasitaemia (with \>90% ring stages) was added to each well, except four wells in row 'A' (A9-A12) which received two per cent non-parasitized cell suspension. The plates were incubated at 37°C in CO2 incubator for 72 h. After which, 100 μl of lysis buffer containing 2× concentration of SYBR Green I was added to each well and incubated for one hour at 37°C. The plates were examined at 485±20 nm of excitation and 530±20 nm of emission for relative fluorescence units per well using the fluorescence plate reader (FLX 800 BIOTEK). The IC~50~ and IC~90~ values (in nM) were determined using non-linear regression analysis of dose-response curves using pre-programmed excel spreadsheet. The resistance factor of MZR-I, -II, -III and -IV parasites in respect to 3D7 and K1 strains was calculated as IC~50~ values obtained against MZR parasites/IC~50~ values obtained against 3D7 or K1 parasites.

###### 

Highest concentration of test samples used for assessment of chemosensitivity against *Plasmodium falciparum*
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*Statistical analysis*: The data were analyzed by two-way ANOVA followed by multiple comparisons using Newman Keuls test (STATISTICA 7.0, StatSoft, USA) to establish significance between IC~50~ and IC~90~ values obtained against reference strains and MZR isolates.

Results {#sec1-3}
=======

The continuous *in vitro* cultures of all the field isolates were successfully maintained in laboratory. Growth profile is depicted in [Table II](#T2){ref-type="table"}. It was evident that the initial %P of all the parasite lines ranged between 1.1 and 1.4 which rose to 8.4 and 9.0 per cent after seven days of cultivation exhibiting identical growth profile of field isolates as well as reference parasite (3D7 and K1) strains.

###### 

Per cent parasitaemia of MZR-I, MZR-II, MZR-III and MZR-IV field isolates, and 3D7 and K1 strains of *Plasmodium falciparum* as observed on eight consecutive days
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Subsequent efforts were made to determine the sensitivity of all four field isolates to nine standard antimalarials and two antibiotics. The IC~50~ and IC~90~ values (in nM) of all the antimalarials and antibiotics obtained against MZR field isolates and 3D7 and K1 parasites are depicted in Tables [III](#T3){ref-type="table"} and [IV](#T4){ref-type="table"}, respectively. The IC~50~ and IC~90~ values of all the standard antimalarials and antibiotics against MZR field isolates and reference parasite strains were almost identical, except K1 strain which exhibited high IC~50~ and IC~90~ values of CQ, for which it was resistant and all the field isolates exhibited higher IC~50~ and IC~90~ values of CQ, quinine and DHA. The IC~50~ and IC~90~ values of CQ and quinine against field isolates were significantly higher (P\<0.001) when compared with 3D7 and K1 strains. The resistance index values of four field isolates to CQ, QUIN and DHA with respect to 3D7 and K1 strains are shown in Tables [V](#T5){ref-type="table"} and [VI](#T6){ref-type="table"}. It was observed that resistant index of all four field isolates, with respect to 3D7 strain, ranged between 260.55 and 403.78 to CQ, 39.83 and 46.42 to quinine and 2.98 and 4.16 to DHA, whereas the respective values to K1 strain ranged between 6.51 and 10.08, 39.26 and 45.75 and 2.65 and 3.71. MZR-I isolate exhibited highest resistance index with respect to 3D7 as well as K1 strain. The high *in vitro* IC~50~ and IC~90~ values of DHA (which is a metabolite of artemisinins[@ref24]) correlated well with ACT treatment failure.

###### 

IC~50~ values of standard antimalarials and antibiotics against laboratory maintained 3D7, K1 strains and field isolates of *Plasmodium falciparum*
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###### 

IC~90~ values of standard antimalarials and antibiotics against laboratory maintained 3D7, K1 strains and field isolates of *Plasmodium falciparum*
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###### 

Resistance index of MZR field isolates in respect to 3D7 (chloroquine sensitive) strain of *Plasmodium falciparum*
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###### 

Resistance index of field isolates in respect to chloroquine-resistant (K1) strain of *Plasmodium falciparum*
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Discussion {#sec1-4}
==========

A large number of studies have been carried out to observe *in vitro* susceptibility of both *P. falciparum* and *P. vivax* isolates to monitor drug resistance[@ref25][@ref26][@ref27][@ref28] from different parts of the world, especially where CQ resistance is prevalent[@ref29]. Wongsrichanalai *et al*[@ref30] have observed the prevalence of high resistance to MQ in Thai-Myanmar border region. There are many consecutive reports claiming spread of Artemisinin ART resistance in Western Cambodia[@ref11][@ref12][@ref14] and a recent report has provided evidence for the presence of artemisinin-resistant falciparum malaria across much of Upper Myanmar, close to the Indian border[@ref20]. Artemisinins are the backbone of malaria therapy as these form the basis of ACTs where artesunate replaces quinine in the treatment of severe malaria[@ref31][@ref32]. As these isolates showed tolerance to DHA-PPQ combination therapy, we planned to explore the *in vitro* susceptibility of these against existing antimalarials and commonly used antibiotics and observed significantly higher IC~50~ (nM) and IC~90~ (nM) values of CQ and quinine compared to reference strains. The increase in IC~50~ and IC~90~ values of DHA was not significant.

In conclusion, our findings showed that these field isolates of *P. falciparum* developed resistant to CQ and quinine but not to DHA as increase in IC~50~ and IC~90~ values of DHA were not significant. These findings indicated that the tolerance to DHA-PPQ combination might be because of PPQ only. Further study is required to establish a genetic correlation with high IC~50~ and IC~90~ values of CQ and QUIN.
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